New 340B Orphan Drug Rule “Equally Invalid” As Previous One – PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
HRSA’s interpretive rule on the exclusion of orphan drugs from the 340B program, issued July 21, restates the policy contained in the substantive rule that the manufacturers group got overturned in federal court.